Periodontitis vaccine and related compositions and methods of use
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10835590-B2
Publication Date
2020-11-17
Expiration Date
Abstract
An immunogenic composition, a periodontal vaccine formulation containing the immunogenic composition, and methods for treating or preventing periodontal disease are provided, where the methods involves administering an immunologically effective amount of the composition or vaccine formulation to a subject. The immunogenic composition contains at least one polypeptide that comprises: an Mfa1 antigen sequence that is substantially homologous to an immunogenic amino acid sequence from an Mfa1 fimbrilin protein of a Porphyromonas bacterium; and an HA1 antigen sequence, an HA2 antigen sequence, or both an HA1 antigen sequence and an HA2 antigen sequence, wherein the HA1 antigen sequence is substantially homologous to an immunogenic amino acid sequence from an RgpA Gingipain hemagglutinin domain 1 contained within an RgpA Gingipain protein of a Porphyromonas bacterium, and the HA2 antigen sequence is substantially homologous to an immunogenic amino acid sequence from an RgpA Gingipain hemagglutinin domain 2 contained within an RgpA Gingipain protein of a Porphyromonas bacterium.
Core Innovation
The invention relates to an immunogenic composition for a periodontal vaccine strategy in periodontal disease. The composition includes at least one recombinant polypeptide comprising an Mfa1 antigen sequence and an HA1 antigen sequence and/or an HA2 antigen sequence, configured as sequences having specified minimum sequence homology to reference SEQ ID NOs.
The Mfa1 antigen sequence has at least 80% sequence homology to SEQ ID NO: 1 or SEQ ID NO: 4. The HA1 antigen sequence comprises a sequence having at least 80% sequence homology to SEQ ID NO: 2 or SEQ ID NO: 5, and the HA2 antigen sequence comprises a sequence having at least 80% sequence homology to SEQ ID NO: 3 or SEQ ID NO: 6.
The document further describes vaccine formulations using the immunogenic composition and indicates therapeutic vaccination and prophylactic vaccination to treat and prevent periodontitis. It also describes in vivo experimental results showing antigen-specific IgG responses and protection from Porphyromonas gingivalis-induced oral bone loss in mice using a combined Mfa1+HA1+HA2 vaccine.
Claims Coverage
The provided claim set includes one independent claim defining the core immunogenic composition, with dependent claims refining antigen sequence homology thresholds, adding excipients/adjuvants, specifying formulation formats, and specifying immunization-related context and use for periodontal disease associated with Porphyromonas species.
Homology-defined recombinant polypeptide immunogenic composition for periodontal vaccination
An immunogenic composition comprising at least one recombinant polypeptide including an Mfa1 antigen sequence (at least 80% sequence homology to SEQ ID NO: 1 or SEQ ID NO: 4) and an HA1 antigen sequence, an HA2 antigen sequence, or both (HA1: at least 80% sequence homology to SEQ ID NO: 2 or SEQ ID NO: 5; HA2: at least 80% sequence homology to SEQ ID NO: 3 or SEQ ID NO: 6).
Across the provided portion, the claim coverage is centered on a homology-defined recombinant polypeptide immunogenic composition combining Mfa1 with HA1 and/or HA2, with dependent refinements addressing selection of reference sequences and inclusion of vaccine formulation components and periodontal disease/Porphyromonas-associated use.
Stated Advantages
Induces antigen-specific IgG responses (ELISA IgG EC50) in vivo.
Provides protection from Porphyromonas gingivalis-induced oral bone loss.
Provides comparable protection across adjuvants including saline delivery.
Documented Applications
Therapeutic vaccination and prophylactic vaccination to treat or prevent periodontitis.
Use in periodontal disease associated with a Porphyromonas bacterium selected from Porphyromonas species including P. gingivalis and other listed Porphyromonas species.
Immunization with intramuscular injection for a vaccine formulation.
Interested in licensing this patent?